Childhood blood cancer (a rare disease) used to be more deadly than adult cancer, but now it's 90%+ survival rate. The reason childhood cancer research can make rapid progress is through recruiting every young patients into randomized clinical trials, which help cut the costs and shortened the time frame of drug development.
Every early stage BC patient should consider neojuvant iSPY-2 clinical trial before surgery, and every late stage or metastatic BC patients should consider a randomized clinical trial. Patients make a difference.
No comments:
Post a Comment